Britain’s savers are pulling money out of their pensions earlier than usual, attempting to get ahead of the introduction of inheritance tax on unspent defined-contribution pensions next April.
Thomas Massie plans to reintroduce articles of impeachment against Pete Hegseth next week, and post-midterm GOP math could work against the Pentagon chief.
Thomas Massie plans to reintroduce articles of impeachment against Pete Hegseth next week, and post-midterm GOP math could work against the Pentagon chief.
Nvidia Corp. is in for tougher scrutiny from a new Democratic majority in Congress that’s set to demand answers from Chief Executive Officer Jensen Huang about whether the company is doing enough to keep its coveted artificial intelligence chips out of the hands of China and other US adversaries.
(RTTNews) - The healthcare sector saw a busy week, with several companies securing regulatory approvals, announcing workforce restructuring, and advancing strategic business deals.
Cult leader Paul Mackenzie was convicted of murdering 190 children and one adult after he ordered his followers to starve themselves to death in order to meet Jesus.
Docebo Inc. reported its financial results for the three months ended September 30, 2026, with total revenue of $70.3 million, representing an increase of 14% from the comparative period in the prior year. Subscription revenue for the quarter was $65.2 million, an increase of 12%
Docebo Inc. reported its financial results for the three months ended September 30, 2026, with total revenue of $70.3 million, representing an increase of 14% from the comparative period in the prior year. Subscription revenue for the quarter was $65.2 million, an increase of 12%
Humana Inc. reported its financial results for the third quarter ended September 30, 2026, with earnings per share of $1.33 on a GAAP basis and an Adjusted loss per share of $0.70. For the nine months ended September 30, 2026, the company reported GAAP earnings per share of $16.8
Pharming Group N.V. announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of the marketing authorization of Joenja, an oral, selective phosphoinositide 3-kinase delta inhibitor, to include children aged 4 to 11 years weighing